Atossa Therapeutics (NASDAQ:ATOS) Stock Rating Reaffirmed by HC Wainwright

Atossa Therapeutics (NASDAQ:ATOS)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $4.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 144.65% from the company’s previous close.

A number of other equities analysts have also recently issued reports on the company. StockNews.com cut Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Atossa Therapeutics in a research report on Friday, January 12th.

Atossa Therapeutics Stock Performance

Shares of ATOS stock traded down $0.08 during mid-day trading on Tuesday, hitting $1.64. 490,364 shares of the stock traded hands, compared to its average volume of 1,340,261. Atossa Therapeutics has a twelve month low of $0.59 and a twelve month high of $2.31. The firm has a market cap of $204.87 million, a price-to-earnings ratio of -6.75 and a beta of 1.19. The company’s 50-day simple moving average is $1.35 and its 200-day simple moving average is $0.97.

Atossa Therapeutics (NASDAQ:ATOS) last issued its quarterly earnings results on Monday, April 1st. The company reported ($0.06) earnings per share (EPS) for the quarter. Analysts forecast that Atossa Therapeutics will post -0.28 earnings per share for the current year.

Insider Activity at Atossa Therapeutics

In other news, Director Jonathan Finn purchased 25,000 shares of the stock in a transaction that occurred on Wednesday, April 10th. The shares were purchased at an average cost of $1.77 per share, for a total transaction of $44,250.00. Following the completion of the purchase, the director now directly owns 25,000 shares of the company’s stock, valued at approximately $44,250. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 7.80% of the company’s stock.

Hedge Funds Weigh In On Atossa Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATOS. UBS Group AG bought a new stake in shares of Atossa Therapeutics in the 3rd quarter valued at approximately $25,000. First Republic Investment Management Inc. grew its stake in shares of Atossa Therapeutics by 79.8% in the 1st quarter. First Republic Investment Management Inc. now owns 25,167 shares of the company’s stock valued at $31,000 after purchasing an additional 11,167 shares during the period. Two Sigma Securities LLC bought a new stake in shares of Atossa Therapeutics in the 2nd quarter valued at approximately $32,000. XTX Topco Ltd bought a new stake in shares of Atossa Therapeutics in the 2nd quarter valued at approximately $50,000. Finally, LPL Financial LLC bought a new stake in shares of Atossa Therapeutics in the 2nd quarter valued at approximately $59,000. 12.74% of the stock is currently owned by institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.